Cargando…
Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation
Relapse is the major cause of treatment failure after allogeneic hematopoietic cell transplantation (alloHCT) for acute leukemia and myelodysplastic syndrome (MDS). Wilms' tumor antigen (WT1) is overexpressed in the majority of acute leukemia and MDS patients and has been proposed as a universa...
Autores principales: | Israyelyan, Anna, Goldstein, Leanne, Tsai, Weimin, Aquino, Lia, Forman, Stephen J., Nakamura, Ryotaro, Diamond, Don J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286541/ https://www.ncbi.nlm.nih.gov/pubmed/25243629 http://dx.doi.org/10.1038/bmt.2014.209 |
Ejemplares similares
-
Mutation Analysis of the WT1 Gene in Myelodysplastic Syndromes
por: Hosoya, Noriko, et al.
Publicado: (1998) -
Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine
por: Wang, Xiuli, et al.
Publicado: (2021) -
Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome
por: Ueda, Yasunori, et al.
Publicado: (2017) -
Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia/myelodysplastic syndromes after a first transplantation
por: Yerushalmi, Yaara, et al.
Publicado: (2022) -
Different recovery patterns of CMV-specific and WT1-specific T cells in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: Impact of CMV infection and leukemia relapse
por: Luo, Xiao-Hua, et al.
Publicado: (2023)